Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action PR...
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further...
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.009 | -1.21621621622 | 0.74 | 0.76 | 0.7205 | 166445 | 0.74266762 | CS |
4 | 0.0009 | 0.123270784824 | 0.7301 | 0.76 | 0.71 | 126407 | 0.73850407 | CS |
12 | -0.429 | -36.9827586207 | 1.16 | 1.335 | 0.71 | 246988 | 0.83024535 | CS |
26 | -0.469 | -39.0833333333 | 1.2 | 1.56 | 0.71 | 179947 | 0.97688591 | CS |
52 | -0.629 | -46.25 | 1.36 | 1.56 | 0.71 | 144672 | 1.00986532 | CS |
156 | -12.379 | -94.4241037376 | 13.11 | 19.285 | 0.71 | 206547 | 3.36906951 | CS |
260 | -25.369 | -97.1992337165 | 26.1 | 43.07 | 0.71 | 213418 | 7.14389734 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.